Evidence map›Paper›PMID 27826529›Full record

ReviewTranslational lung cancer research2016

Exosomes genetic cargo in lung cancer: a truly Pandora's box.

Pablo Reclusa, Rafael Sirera, Antonio Araujo, Marco Giallombardo, Anna Valentino, Laure Sorber, Ignacio Gil Bazo, Patrick Pauwels, Christian Rolfo

Abstract readReview
In one paragraph

Review in Translational lung cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Small Extracellular Vesicles Harboring PD-L1 in Obstructive Sleep Apnea.International journal of molecular sciences · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Exosomes: A Promising Avenue for the Diagnosis of Breast Cancer.Technology in cancer research & treatment · 2019
    Review
  15. Article
  16. MutantThe oncologist · 2018
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pablo ReclusaPhase I- Early Clinical trials Unit, Oncology Department & Center for Oncological Research (CORE) Antwerp University Hospital, Antwerp, Belgium.
Rafael SireraDepartment of Biotechnology, Politechnic University of Valencia Hospitality Centre of Oporto, Valencia, Spain.
Antonio AraujoDepartment of Medical Oncology, Centro Hospitalar do Porto, Porto, Portugal.
Marco GiallombardoPhase I- Early Clinical trials Unit, Oncology Department & Center for Oncological Research (CORE) Antwerp University Hospital, Antwerp, Belgium.
Anna ValentinoPhase I- Early Clinical trials Unit, Oncology Department & Center for Oncological Research (CORE) Antwerp University Hospital, Antwerp, Belgium.
Laure SorberMolecular Pathology Unit, Antwerp University Hospital & Center for Oncological Research (CORE) Antwerp University Hospital, Antwerp, Belgium.
Ignacio Gil BazoDepartment of Medical Oncology, University of Navarra, Pamplona, Spain.
Patrick PauwelsMolecular Pathology Unit, Antwerp University Hospital & Center for Oncological Research (CORE) Antwerp University Hospital, Antwerp, Belgium.
Christian RolfoPhase I- Early Clinical trials Unit, Oncology Department & Center for Oncological Research (CORE) Antwerp University Hospital, Antwerp, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is a highly lethal disease. Targeted therapies have been developed in last years, however survival rates are not improving due to the delay in the diagnosis, making biomarkers one of the most interesting fields of study in cancer. Liquid biopsy has raised as an alternative to tissue biopsy due to improvements in analytical techniques for circulating tumor cells (CTCs), cell free DNA and exosomes. Among all, exosomes have raised as one of the most promising tools to understand the tumor due to their stability in the blood and their similarity to the cells of origin. In the last years, different alterations have been described inside the exosomes derived from non-small cell lung cancer (NSCLC) cells mirroring the processes inside these tumoral cells, such as

Indexed as

exosomesliquid biopsyncRNAsNon-small cell lung cancer (NSCLC)

Identifiers

PMID27826529
PMCPMC5099517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.